Lobbying client
CARY PHARMACEUTICALS
a pharmaceutical development company-smoking cessationm catheter technology
Filings
3
Filed by
1
Reported in-house
—
Reported by firms
$50,000
Reported lobbying by year
The larger of in-house and firm-reported each year, $ thousands
2012 to 2013
Filings
3 filings, newest first.
| Filing | Filed by | Amount |
|---|---|---|
|
1st Quarter - Termination (No Activity) 1st Quarter 2013
|
THE CONAFAY GROUP, LLC | $30,000 reported |
|
4th Quarter - Report (No Activity) 4th Quarter 2012
|
THE CONAFAY GROUP, LLC | $20,000 reported |
|
Registration 4th Quarter 2012
|
THE CONAFAY GROUP, LLC | — reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| THE CONAFAY GROUP, LLC | 2 | $50,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Health Issues | HCR | 1 |
| Medical/Disease Research/Clinical Labs | MED | 1 |
| Budget/Appropriations | BUD | 1 |
| Science/Technology | SCI | 1 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.